Plasticizer exposure health study
Part of Blood & lymphatic, Brain & nervous system, Cancer, Genetic & congenital, Heart & circulation clinical trials.
This study looks at how plastic chemicals (called plasticizers) affect people with different health conditions, such as thalassemia (a blood disorder), brain tumors, or brain bleeds. It compares their exposure levels to healthy adults to understand the impact on health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 years or older).
- You cannot have any plastic medical implants (like tubes or devices made of plastic).
- You cannot have an active infection or infectious disease.
- You cannot be pregnant.
- The specific eligibility for your condition will be checked separately.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
This study tests a special system (Hemanext One) that stores red blood cells with less oxygen, to see if it helps people with thalassemia who need regular transfusions. It may reduce side effects or improve how well the transfusions work.
This trial tests a new treatment called KL003 for people with beta-thalassemia who need regular blood transfusions. The treatment uses your own stem cells (collected from your blood) to try to reduce or stop the need for transfusions.
This study tests an experimental drug called YOLT-204 to see if it is safe and can help people with transfusion-dependent beta-thalassemia need fewer blood transfusions. It is for adults aged 18 to 35 who have a specific type of thalassemia and are otherwise healthy enough for the trial.
This trial tests a new drug, 9MW3011, in people with a type of beta-thalassemia that does not require regular blood transfusions. The goal is to see if the drug can safely help manage iron overload and improve hemoglobin levels.
This trial studies an investigational medicine in adults with beta thalassemia intermedia (including non-transfusion dependent thalassemia). The goal is to see how well the treatment works and how safe it is for people whose hemoglobin runs in a certain range.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.